CD88 (C5aR1) Monoclonal Antibody (S5/1), Functional Grade, eBioscience™, Invitrogen™

Description

• Description: This S5/1 monoclonal antibody recognizes human CD88 also known as C5aR1
• C5aR1 is a complement receptor widely expressed on cells of the myeloid lineage
• Clone S5/1 has been reported to block C5a binding
• Applications Reported: This S5/1 antibody has been reported for use in flow cytometric analysis
• S5/1 has also been reported for blocking activity
• Applications Tested: This S5/1 antibody has been tested by flow cytometric analysis of normal human peripheral blood cells
• This may be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Storage and handling: Use in a sterile environment
• Filtration: 0.2 μm post-manufacturing filtered
• Purity: Greater than 90%, as determined by SDS-PAGE
• Endotoxin Level: Less than 0.001 ng/μg antibody, as determined by LAL assay
• Aggregation: Less than 10%, as determined by HPLC
• CD88, also known as C5aR1, is a C5a Anaphylatoxin Receptor that mediates the effects of one of the most potent chemotactic agents known
• C5AR1 has been implicated in asthma, and its expression has been reported in myeloid blood cells, brain, liver, lung, spleen, heart, kidney, and intestinal tract
• CD88 is the receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a
• Functionally, CD88 stimulates chemotaxis, granule enzyme release and superoxide anion production
• CD88 is also a component of the classical pathway of the complement cascade; it may be involved with tissue injury associated with ischemia or sepsis and it may be a component of the membrane attack complex
• Diseases associated with CD88 include Mannose-Binding Lectin Deficiency and Systemic Lupus Erythematosus.